A study to evaluate the efficacy of daily carboplatin plus concurrent thoracic radiation followed by durvalumab for patients with stage III NSCLC who have a PS of 2 and/or are older

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2023 Primary endpoint (12-month progression-free survival (PFS)) has been met, as per results presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Results (n=86; from September 2019 to October 2021) assessing the efficacy and safety of carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients, presented at the 48th European Society for Medical Oncology Congress.
05 May 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com